Cancer remains a major global health issue, with researchers striving to develop more effective targeted therapies. Among all cancer types, breast cancer is a leading cause of death in women worldwide. The high mortality rate of breast cancer is attributed not only to the aggressive subtypes and tumor heterogeneity but also to the complex molecular mechanisms underlying its metastasis and therapy resistance. Epithelial-to-mesenchymal transition (EMT) is instrumental in contributing towards the aggressiveness and metastatic potential. MicroRNAs (miRNAs) are small, noncoding RNA molecules that regulate gene expression posttranscriptionally. One key miRNA, miR-200c, plays a vital role in suppressing EMT by targeting the transcriptional repressor of E-cadherin such as ZEB1 and ZEB2, thereby preserving epithelial characteristics. In addition to its role in EMT, miR-200c also affects cancer stem ness, immune response, and resistance to treatment, making it a strong candidate for both diagnostic and therapeutic applications. The downregulation of miR200c is associated with poor patient survival and high-grade tumors like TNBC. Its presence in blood and exosomes provides a noninvasive method for early detection and disease monitoring. Experimental therapies involving miR-200c like nanoparticle-based delivery systems or drugs that reactivate its expression have shown encouraging results in reducing tumor growth and improving drug response. miR200c can be a compelling target for diagnostic and therapeutic purpose in breast cancer, due to its ability to modulate cancer hallmarks. Further research in the direction of optimized delivery system and clinical validation is crucial to harness the potential of miR200c against breast cancer.